Biomarker landscape in advanced NSCLC: insights from a national prospective registry


Por: Provencio, M, Cobo, M, Rodriguez-Abreu, D, Carcereny, E, Calvo, V, Castro, RL, Bernabé, R, Bruno, MF, Bosch-Barrera, J, del Barco, E, Medina, K, Sanchez-Hernandez, A, Suay, G, Ortega, AL, Vázquez, S, Lazaro-Quintela, M, Guirado, M, Estival, A, Blanco, M, Cantero, A and Massutí, B

Publicada: 1 sep 2025 Ahead of Print: 1 jul 2025
Resumen:
Objectives: The determination of actionable genes is a necessity in lung cancer for proper care practice. The Spanish Lung Cancer Group (Fundacion GECP) has performed an exploratory analysis of this aspect, specifically in stage IV non-small cell lung cancer (NSCLC). Materials and methods: The Thoracic Tumor Registry (TTR) is a Spanish prospective, observational cohort study. At the time of data extraction (March 2024), 27,399 patients were enrolled from 82 hospitals. Results: There were 13,583 patients with stage IV NSCLC. The analysis of at least one tumor marker was performed in 85.7 % of non-squamous and 62.8 % of squamous patients (p-value < 0.001), with differences between autonomous communities. In the non-squamous population, the three most frequently analysed markers were EGFR (77.3 %), ALK (66.1 %) and PD-L1 (56.3 %). Biomarker profiling has undergone a more pronounced and extensive development in squamous histology in recent years. Molecular determinations that do not have a generally approved targeted therapy have also increased. Biomarker testing in patients with ECOG PS 2 is lower compared to ECOG PS < 2 (77.6 % vs 82.6 %, p-value < 0.001). Sub-analysis shows rates also vary by hospital size. Conclusion: The analysis of tumor markers in stage IV NSCLC patients continues to increase in Spain, at the same level as in Europe o USA, despite the absence of national plans. There are clinically guided determinations that are rare in squamous histology but have an appreciable percentage of positivity. Even in patients with ECOG PS2, biomarker testing with high clinical suspicion should be considered.

Filiaciones:
Provencio, M:
 Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain

 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

Cobo, M:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Reg & Virgen Victoria Univ Hosp, IBIMA, Med Oncol Interctr Unit, Malaga, Spain

Rodriguez-Abreu, D:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Hosp Univ Insular Gran Canaria, Las Palmas Gran Canaria, Spain

:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Hosp Badalona Germans Trias & Pujol, IGTP, B ARGO, Catalan Inst Oncol, Barcelona, Spain

Calvo, V:
 Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain

 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

Castro, RL:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Hosp Clin Univ Valladolid, Valladolid, Spain

Bernabé, R:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Hosp Univ Virgen Rocio, Seville, Spain

Bruno, MF:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Complejo Hosp Univ A Coruna, La Coruna, Spain

Bosch-Barrera, J:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Hosp Univ Dr Josep Trueta, Inst Catala Oncol, Girona, Spain

 Inst Invest Med Girona IDIBGI, Precis Oncol Grp OncoGIR Pro, Girona, Spain

del Barco, E:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Hosp Univ Salamanca IBSAL, Salamanca, Spain

Medina, K:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Hosp Univ Nuestra Senora Candelaria, Santa Cruz de Tenerife, Spain

Sanchez-Hernandez, A:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Consorcio Hosp Prov Castellon, Castellon de La Plana, Spain

Suay, G:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Hosp Univ & Politecn La Fe, Valencia, Spain

Ortega, AL:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Hosp Univ Jaen, Jaen, Spain

Vázquez, S:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Hosp Univ Lucus Augusti, Lugo, Spain

Lazaro-Quintela, M:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Complexo Hosp Univ Vigo, Vigo, Spain

Guirado, M:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Hosp Gen Univ Elche, Alicante, Spain

Estival, A:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Hosp Univ Insular Gran Canaria, Las Palmas Gran Canaria, Spain

Blanco, M:
 Hosp Univ Puerta Hierro Majadahonda, Madrid, Spain

 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

Cantero, A:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Reg & Virgen Victoria Univ Hosp, IBIMA, Med Oncol Interctr Unit, Malaga, Spain

Massutí, B:
 Spanish Lung Canc Grp Fdn GECP, Barcelona, Spain

 Hosp Gen Univ Dr Balmis Alicante, Alicante, Spain
ISSN: 01695002





Lung Cancer
Editorial
Elsevier BV, ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND, Países Bajos
Tipo de documento: Article
Volumen: 207 Número:
Páginas: 108680-108680
WOS Id: 001610697400001
ID de PubMed: 40749260

MÉTRICAS